Compare Eni SpA (E) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Neurocrine Biosciences Inc — how do they compare? Eni SpA trades at $48.16 (market cap $70.34B), while Neurocrine Biosciences Inc trades at $171.77 (market cap $17.30B). The key difference: Eni SpA is far larger — about 4.1× Neurocrine Biosciences Inc's market cap, and Eni SpA pays a 4.99% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| E | NBIX | |
|---|---|---|
Market Cap | $70.34B | $17.30B |
Sector | Energy | Health |
52-Week High | $57.61 | $180.55 |
52-Week Low | $32.93 | $123.10 |
Enterprise Value | $89.25B | $16.39B |
Dividend Yield | 4.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $48.11, down 2.91% over 24 hours, with a bullish technical signal supported by moving averages but mixed oscillators. The company shows stable cash flow generation with $238 million net cash flow in 2025, though revenue has declined from $132.5B in 2022 to $82.2B in 2025. Recent strategic moves include expanding into lithium, battery storage, and fusion energy partnerships, signaling diversification beyond traditional oil and gas.
The outlook balances diversification efforts against revenue pressures; the stock's low P/S of 0.79 and EV/EBITDA of 3.83 suggest undervaluation, but investors face risks from oil price volatility and execution challenges in new ventures. Analyst consensus is cautious with 61.53% hold ratings, reflecting uncertainty amid transition initiatives.
Neurocrine Biosciences (NBIX) trades at $172.14, up 0.09% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 98.17% gross margins and 21.55% net income margin, supported by revenue growth from $2.86B to $3.1B projected. Recent news highlights pipeline advancements including Phase 2 studies and positive clinical data presentations at ENDO 2026.
NBIX presents compelling investment potential with 86% analyst buy ratings and $195.75 consensus target, offering 14% upside. Key catalysts include Q2 earnings on July 30 and continued pipeline execution. Risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's valuation at 26.47 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
